March 2004
Investment Dealers' Digest;3/8/2004, Vol. 70 Issue 10, p30
Trade Publication
Cites developments on initial public offerings (IPO) in the U.S. as of March 3, 2004. Prices; IPO filed by Acadia Pharmaceuticals, Almylam Holding, Archipelago and Cascade Microtech and Inhibitex; Withdrawal activities.


Related Articles

  • Acadia Raises $89.1M Publicly To Fund Upcoming CNS Trials. Shrine, Jim // BioWorld Today;4/6/2007, Vol. 18 Issue 67, p1 

    The article reports on the move of Acadia Pharmaceuticals Inc. to price an $89.1 million public offering after capitalizing on the recent jump in its shares. It says that the San Diego, California-based company sold 5.75 million shares at $15.50 per share. It also says that underwriters have a...

  • THE IPO 100.  // Investment Dealers' Digest;1/10/2005, Vol. 71 Issue 1, p16 

    This article focuses on the most recent 100 initial public offerings of the U.S. Some of the Initial Public Offerings (IPOs) are: MHI Hospitality; OtekoTelecommunications; Warren Resources; Arbinet Thexchange; Advance Arner Cash Advance; Cambridge Display Technology; Feldman Mall Properties;...

  • THE IPO 100.  // Investment Dealers' Digest;6/7/2004, Vol. 70 Issue 23, p33 

    Presents data on 100 initial public offerings in the U.S. as of June 2004. Offer price; Number of IPOs and filings since February 2004; Aftermarket; Global Signal; Almylam Pharmaceuticals; Acadia Pharmaceuticals.

  • Record year on capital markets; can the industry do it again? Winter, Peter // BioWorld Insight;1/13/2014, Vol. 22 Issue 2, p1 

    The article focuses on the performance of biotech industry including biopharmacy in 2013 which led to speculations that the industry will be able to perform at the same level in 2014. Topics discussed include the BioWorld Blue Chip Index, the BioWorld Emerging Biotech Index, and the performance...

  • Acadia Makes New Move for an IPO. Webb, Marion // San Diego Business Journal;3/8/2004, Vol. 25 Issue 10, p8 

    Reports developments in the pharmaceutical industry in California as of March 2004. Attempt of Acadia Pharmaceuticals Inc. to go public; Deal between Neurocrine Biosciences Inc. and Wyeth Inc.; Recommendation received by CancerVax Corp. for its Canvaxin trials.

  • Financings Roundup.  // BioWorld Today;5/22/2013, Vol. 24 Issue 98, p2 

    The article offers financing news briefs in the pharmaceutical industry in the U.S. and Europe as of May 22, 2013. Acadia Pharmaceuticals Inc. has completed the public offering of its 9.2 million shares to support clinical trials, development, and commercialization of pimavanserin against...

  • Week in Review.  // BioWorld Insight;5/28/2013, Vol. 21 Issue 22, p5 

    The article presents news briefs related to pharmaceutical industry as of May 28, 2013. Acadia Pharmaceuticals Inc. has closed its public offering for gross proceeds of 115 million U.S. dollars. Portola Pharmaceuticals Inc. has raised 122 million U.S. dollars from its initial public offering...

  • Why are so many new stock issues underpriced? Saunders, Anthony // Business Review (Federal Reserve Bank of Philadelphia);Mar/Apr90, p3 

    Examines the reasons for initial public equity offerings (IPO) underpricing and evaluate the degree to which underpricing is due to Glass-Steagall restrictions. Evidence on underpricing; Reasons why underpricing occurs; Implications of monopoly-power hypothesis for bank regulation; Conclusion.

  • Is Underpricing a Signal of Firm Quality? Jain, Bharat A. // American Business Review;Jan1996, Vol. 14 Issue 1, p38 

    This paper attempts to estimate the relationship between IPO underpricing and the post-IPO operating performance of newly public firms. Recent papers in the IPO literature posit that issuers deliberately underprice their stock at the IPO to signal post-IPO firm quality. The results of this study...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics